Published by Global Banking & Finance Review®
Posted on August 28, 2025
1 min readLast updated: January 22, 2026
Add as preferred source on GoogleStada plans an IPO in autumn if conditions are right, says CEO. The company saw a 5% rise in first-half EBITDA.
FRANKFURT (Reuters) -German generic drugmaker Stada is reviving plans to go public during the autumn if market conditions are supportive, its CEO told news agency dpa on Thursday.
"We are preparing an IPO in the autumn, provided the general conditions are right," Peter Goldschmidt was quoted as saying.
Financial advisers told Reuters last month they view Stada as a candidate for an initial public offering during the second half, alongside prosthetics maker Ottobock, Deutsche Boerse's research and technology unit ISS Stoxx and classifieds business Swiss Marketplace Group.
Stada, held by private equity firms Bain Capital and Cinven, has previously said it was deliberating with its investors all options regarding future ownership, including an IPO and a sale.
Also on Thursday, Stada reported that first-half earnings before interest, tax, depreciation, amortization (EBITDA) and one-off items rose a currency-adjusted 5% to 481 million euros ($563 million).
Initial IPO plans were put on hold in March.
($1 = 0.8542 euros)
(Reporting by Ludwig Burger, editing by Thomas Seythal)
Stada is preparing for an initial public offering in the autumn if market conditions are supportive, according to CEO Peter Goldschmidt.
Stada reported that its first-half EBITDA rose a currency-adjusted 5% to 481 million euros ($563 million).
Stada is currently held by private equity firms Bain Capital and Cinven.
Stada's initial IPO plans were put on hold in March.
Prosthetics maker Ottobock is also viewed as a candidate for an initial public offering during the second half of the year.
Explore more articles in the Finance category
